Patent · US Active

Alphavirus neoantigen vectors

US11504421B2 · kind B2 · utility

0Cited by
103References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 8, 2018
Grant dateNov 22, 2022
Priority date
Expiry dateMay 8, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2770/36143
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.